/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

CLEARSIDE BIOMEDICAL INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.5805 -0.3333(-33.33%) CLSD at 26 Nov 2025 05:48 PM Biotechnology
Lowest Today 0.6
Highest Today 0.799
Today’s Open 0.7801
Prev. Close 0.8999
52 Week High 17.10
52 Week Low 0.59
Day’s Range: Low 0.6 High 0.799
52-Week Range: Low 0.59 High 17.10
1 day return -
1 Week return -78.83
1 month return -83.93
3 month return +54.24
6 month return -24.4
1 year return -42.57
3 year return -45.11
5 year return -68.19
10 year return -

Institutional Holdings

Vanguard Group Inc 0.29

Vanguard Total Stock Mkt Idx Inv 0.16

Carmignac Gestion 0.13

Carmignac Pf L-S Eurp Eqs F EUR Acc 0.13

Vanguard Institutional Extnd Mkt Idx Tr 0.07

Geode Capital Management, LLC 0.07

BlackRock Inc 0.05

GSA Capital Partners LLP 0.05

Renaissance Technologies Corp 0.04

Fidelity Extended Market Index 0.03

First Manhattan Co. LLC 0.03

State Street Corp 0.02

Bridgeway Capital Management, LLC 0.02

Bridgeway Ultra-Small Company Market 0.02

Northern Trust Corp 0.01

Fidelity Total Market Index 0.01

Assenagon Asset Management SA 0.01

Morgan Stanley - Brokerage Accounts 0.01

Extended Equity Market Fund K 0.01

PNC Financial Services Group Inc 0.01

Brown Wealth Management, LLC 0.01

Fidelity Series Total Market Index 0.01

Northeast Financial Consultants, Inc 0.01

Northern Trust Extended Eq Market Idx 0.01

NT Ext Equity Mkt Idx Fd - L 0.01

Susquehanna International Group, LLP 0.01

CapTrust Financial Advisors 0.01

Spartan Extended Market Index Pool F 0.01

NT Ext Equity Mkt Idx Fd - NL 0.01

Vanguard Instl Ttl Stk Mkt Idx InstlPls 0.00

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.00

Fidelity Nasdaq Composite Index 0.00

Invesco Technology S&P US Sel Sec ETF 0.00

Spartan Total Market Index Pool G 0.00

Stifel Financial Corp 0.00

Investor's Fiduciary Advisor Network, LLC 0.00

UBS Group AG 0.00

Vanguard Balanced Index Inv 0.00

Blackrock US Eq Mkt Fund CF 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

Market Status

Strong Buy: 4

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 4.71 M

PB Ratio 3.927

PE Ratio 0.0

Enterprise Value -1.75 M

Total Assets 25.13 M

Volume 1254267

Company Financials

Annual Revenue FY23:2211000 2.2M, FY22:1327000 1.3M, FY21:29575000 29.6M, FY20:7894000 7.9M, FY19:2173000 2.2M

Annual Profit FY23:1652000 1.7M, FY22:1123000 1.1M, FY21:29575000 29.6M, FY20:7894000 7.9M, FY19:2173000 2.2M

Annual Net worth FY23:-37316000 -37.3M, FY22:-34071343 -34.1M, FY21:376000 0.4M, FY20:-18030000 -18.0M, FY19:-30559000 -30.6M

Quarterly Revenue Q3/2025:201000 0.2M, Q2/2025:492000 0.5M, Q1/2025:2330000 2.3M, Q3/2024:1038000 1.0M, Q2/2024:90000 0.1M

Quarterly Profit Q3/2025:201000 0.2M, Q2/2025:408000 0.4M, Q1/2025:2082000 2.1M, Q3/2024:1038000 1.0M, Q2/2024:90000 0.1M

Quarterly Net worth Q3/2025:-5972000 -6.0M, Q2/2025:-4495000 -4.5M, Q1/2025:-8223000 -8.2M, Q3/2024:-7688000 -7.7M, Q2/2024:-7594000 -7.6M

Fund house & investment objective

Company Information Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Organisation Biotechnology

Employees 32

Industry Biotechnology

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow